Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study

Hirata, Koichi; Ueda, Kaname; Komori, Mika; Zagar, Anthony; Selzler, Katherine J.; Nelson, Ann Marie; Han, Yimei; Jaffe, Dena H; Matsumori, Yasuhiko; Takeshima, Takao

doi:10.1080/03007995.2021.1971179

Cited by 34 publications

(80 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OVERCOME (Japan) was similar in study design to the earlier OVERCOME (US) observational study [ 14 ], and the design has been previously described [ 7 ]. Briefly, the survey consisted of three stages.…”

Section: Methodsmentioning

confidence: 99%

“…Briefly, the survey consisted of three stages. In Stage I, a respondent sample representative of the Japanese population was selected using preset demographic sample size quotas for sex, age, and geographic region (quotas based on Japanese census data [ 7 ]). In Stage II, people with migraine and severe headache were identified according to the following criteria: at least one headache in the previous 12 months not associated with another illness, head injury, or a hangover; and either met modified criteria for migraine from the International Classification of Headache Disorders, 3rd edition (ICHD-3) [ 15 ] or had a self-reported physician diagnosis of migraine.…”

Section: Methodsmentioning

confidence: 99%

“…As previously described [ 7 ], participants were included in the survey if they were adults resident in Japan, members of the Kantar Profiles (Lightspeed) online global survey panel or its panel partners, with access to the internet, able to read and write Japanese, and able to provide electronic informed consent.…”

Section: Methodsmentioning

confidence: 99%

“…Migraine is known to have substantial impacts on quality of life, everyday function, familial relationships, and work productivity [ 2 – 4 ]. In Japan, where migraine is estimated to affect 6.0–8.6% of the population [ 5 – 7 ], the individual, economic, and societal impacts of migraine are starting to be recognized [ 8 , 9 ]. The economic impact of headache (including migraine), combined with the relative inaccessibility of specialist medical care for many patients [ 4 ], has led to a proposed structured framework for headache health care that appears to be both effective and cost-effective for migraine (using European countries as a model [ 10 , 11 ]).…”

Section: Introductionmentioning

confidence: 99%

“…The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]), a cross-sectional observational study, assessed symptomatology, burden, and care patterns in a representative sample of the Japanese population. The study design and broad-scale epidemiological data from the OVERCOME (Japan) study have been published previously [ 7 ]. Here we describe in detail the burden of migraine and barriers to migraine care in Japan revealed by OVERCOME (Japan).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study

Matsumori,

Ueda,

Komori

et al. 2021

Neurol Ther

Self Cite

View full text Add to dashboard Cite

Introduction The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVERCOME [Japan]) assessed the impact and burden of migraine in Japan. Methods OVERCOME (Japan) was a cross-sectional, observational, population-based web survey of Japanese people with migraine conducted between July and September 2020. The burden and impact of migraine were assessed using the Migraine Disability Assessment (MIDAS), Migraine-Specific Quality-of-Life Questionnaire (MSQ), Migraine Interictal Burden Scale (MIBS-4), and Work Productivity and Activity Impairment-Migraine scale. Results were stratified by average number of monthly headache days (0–3, 4–7, 8–14, ≥ 15). Results In total, 17,071 Japanese people with migraine completed the survey. Of these, 14,033 (82.2%) met International Classification of Headache Disorders, 3rd edition criteria for migraine and 9667 (56.6%) reported a physician diagnosis of migraine. Overall, 20.7% of respondents experienced moderate-to-severe disability (MIDAS). Moderate-to-severe interictal burden (MIBS-4) was experienced by 41.5% of respondents. MSQ scores in all domains were lowest in respondents with the most frequent headaches (≥ 15 monthly headache days) and highest in those with the lowest frequency headaches (≤ 3 monthly headache days), indicating poorer quality of life in those with more frequent headaches. Work time missed due to migraine (absenteeism) increased with increasing headache frequency, from 3.8 to 6.2%; presenteeism affected 29.8–49.9% of work time. Although migraine burden was greatest in people with the most frequent headaches, those with the lowest headache frequency still experienced substantial disability, interictal burden, and impacts on productivity and quality of life. There was also substantial unmet need for migraine care: 36.5% of respondents had ever hesitated to seek medical care for their headaches, and 89.8% had never used preventive medication. Conclusion In Japan, the burden of migraine and barriers to migraine care are substantial. Improving patient awareness and healthcare provider vigilance may help improve patient outcomes. Supplementary Information The online version contains supplementary material available at 10.1007/s40120-021-00305-9.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study

Matsumori,

Ueda,

Komori

et al. 2021

Neurol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction: Using data from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE study in Japan (OVER-COME [Japan]), we describe the current status of the acute treatment of migraine in Japan. Methods: OVERCOME (Japan) was a crosssectional, observational, population-based web survey of people with migraine in Japan (met modified International Classification of Headache Disorders criteria or had a physician

show abstract

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction This MONONOFU trial subgroup analysis evaluates the efficacy of lasmiditan across patient and migraine characteristics in Japanese patients with migraine. Methods MONONOFU trial was a multicenter, randomized, double-blind, placebo-controlled study. The patients were randomly assigned in a 3:7:6:7 ratio to receive lasmiditan 50 mg, 100 mg, 200 mg, or placebo for a single migraine attack within 4 h of pain onset. Efficacy of lasmiditan vs placebo was evaluated at 2 h post dose for proportion of patients with headache pain freedom. Efficacy was assessed across patient characteristics (age, sex, body weight, cardiovascular risk factors (CVRF), and comorbidity of tension-type headache), migraine disease characteristics (history of migraine with aura, migraine prevention therapy, triptan response, and triptan use or nonuse), and migraine attack characteristics (headache severity, aggressive headache, attack during perimenstrual period, time to dosing, time of dosing, experienced treatment-emergent adverse event (TEAE) of dizziness, and experienced TEAE of somnolence). Logistic regression was used; all subgroup analyses were not analyzed with multiplicity-adjusted statistical tests. Results Treatment-by-subgroup interactions (by each arm) were not significant ( p ≥ 0.05) for pain freedom at 2 h post dose across all patient subgroups and lasmiditan doses, except for CVRF (100 mg and 200 mg), migraine with aura (50 mg), triptan response (50 mg), and time to dosing (200 mg). Treatment-by-subgroup interactions (by overall) were not significant ( p ≥ 0.05) for pain freedom at 2 h post dose across all patient subgroups, except for CVRFs. Higher proportions of patients were pain free at 2 h post dose when treated with lasmiditan (50 mg, 100 mg, and 200 mg) versus placebo, irrespective of most patient characteristics, migraine disease characteristics, and migraine attack characteristics. Conclusion Although few interactions were observed, lasmiditan could be a promising acute treatment option in a wide range of Japanese patients with migraine, as efficacy is not generally influenced by patient and migraine characteristics. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02304-0.

show abstract

Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study

Cited by 34 publications

References 33 publications

Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study

Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study

Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial

Contact Info

Product

Resources

About